Adams Micah S, Mensink Ronald P, Plat Jogchum, Winkens Bjorn, Joris Peter J
Department of Nutrition and Movement Sciences, NUTRIM Research Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Universiteitssingel 50, PO Box 616, 6200 MD, Maastricht, The Netherlands.
Department of Methodology and Statistics, CAPHRI Care and Public Health Research Institute, Maastricht University Medical Center+, 6200 MD, Maastricht, The Netherlands.
Eur J Nutr. 2024 Dec 24;64(1):54. doi: 10.1007/s00394-024-03566-w.
The dietary egg-protein hydrolysate Newtricious (NWT)-03 has previously demonstrated improvements in blood pressure and metabolic profiles. However, the long-term effects on vascular function and cardiometabolic risk markers are unknown.
Forty-four older (aged 60-75) adults with overweight/obesity experiencing elevated Subjective Cognitive Failures (SCF) were randomized into a 36-week, double-blind, placebo-controlled trial. Participants either consumed 5.7 g of an egg-protein hydrolysate (NWT-03) or maltodextrin placebo. Endothelial function (brachial artery flow-mediated vasodilation [FMD] and carotid artery reactivity [CAR] responses after a cold pressor test), arterial stiffness (carotid-to-femoral pulse wave velocity [PWV]), retinal microvascular calibers, and cardiometabolic risk markers (insulin sensitivity using a 7-point oral glucose tolerance test, serum lipid profiles, and blood pressure) were evaluated.
FMD observed a non-significant trend towards a 0.3 percentage point (pp) increase in the intervention compared to the placebo group (95% CI: [0.0, 0.7]; p = 0.08), and a significant intervention effect was observed on CAR responses based on a 0.7 pp improvement after a cold pressor test (95% CI: [0.1, 1.3]; p = 0.03). No significant overall changes were observed for arterial stiffness as measured by PWV. Retinal microvascular calibers and cardiometabolic parameters also did not change.
Long-term supplementation with 5.7 g of the egg-protein hydrolysate NWT-03 for 36 weeks improved vascular endothelial function in older adults with overweight/obesity experiencing elevated SCF, which may benefit cardiovascular disease risk. No overall changes in other vascular function markers, retinal microvascular calibers or cardiometabolic risk markers were observed.
The study was registered at ClinicalTrials.gov in January 2021 as NCT04831203: https://clinicaltrials.gov/study/NCT04831203.
膳食鸡蛋蛋白水解物Newtricious（NWT）-03此前已证明可改善血压和代谢状况。然而，其对血管功能和心脏代谢风险标志物的长期影响尚不清楚。
44名年龄在60 - 75岁、超重/肥胖且主观认知失误（SCF）升高的老年人被随机分为一项为期36周的双盲、安慰剂对照试验。参与者分别食用5.7克鸡蛋蛋白水解物（NWT-03）或麦芽糊精安慰剂。评估内皮功能（冷加压试验后肱动脉血流介导的血管舒张[FMD]和颈动脉反应性[CAR]）、动脉僵硬度（颈动脉至股动脉脉搏波速度[PWV]）、视网膜微血管口径以及心脏代谢风险标志物（使用7点口服葡萄糖耐量试验评估胰岛素敏感性、血清脂质谱和血压）。
与安慰剂组相比，干预组的FMD有非显著趋势的0.3个百分点（pp）增加（95%CI：[0.0, 0.7]；p = 0.08），并且基于冷加压试验后0.7 pp的改善，观察到干预对CAR反应有显著效果（95%CI：[0.1, 1.3]；p = 0.03）。通过PWV测量的动脉僵硬度未观察到显著的总体变化。视网膜微血管口径和心脏代谢参数也未改变。
对超重/肥胖且SCF升高的老年人长期补充5.7克鸡蛋蛋白水解物NWT-03持续36周可改善血管内皮功能，这可能有益于心血管疾病风险。未观察到其他血管功能标志物、视网膜微血管口径或心脏代谢风险标志物的总体变化。
该研究于2021年1月在ClinicalTrials.gov注册为NCT04831203：https://clinicaltrials.gov/study/NCT04831203 。
